The chart is not accessible to screen readers. Please switch to the table view to access the data.
Advertisement
Advertisement
Cost-sharing for generic and brand name drugs in the Medicare Part D coverage gap in 2019
Medicare Part D coverage gap cost-sharing for brand and generic drugs 2019
This graph depicts cost-sharing for generic and brand name drugs (including biologics) in the Medicare Part D coverage gap in the U.S. in 2019. During this year, those enrolled in Medicare Part D had a 25 percent co-payment for brand name drugs and biologics in the coverage gap, compared to 37 percent for generic drugs.
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Other statistics that may interest you Statistics on
About the industry
10
- Basic Statistic Spending change on branded and generic medicines in the U.S. 2014-2021
- Premium Statistic Generic market share value change worldwide 2006 vs. 2016, by region
- Premium Statistic Brand and generic prescription medication spending in the U.S. 2006-2021
- Premium Statistic U.S. spending on therapeutic oncology and supportive care by type 2011-2015
- Basic Statistic Citalopram out of pocket price in the U.S. 2004-2023
- Premium Statistic Total savings through generic drug usage in the U.S. by state 2024
- Premium Statistic Generics share of prescription spending in the U.S. by formulation 2012 vs. 2017
- Basic Statistic Tramadol out-of-pocket cost U.S. 2004-2023
- Basic Statistic Azithromycin out-of-pocket cost in the U.S. 2004-2023
- Premium Statistic Adjusted and unadjusted generic prescription growth in U.S. 2020-2023
About the region
10
- Premium Statistic Biosimilars approved for marketing Europe vs U.S. 2022 by year since approval
- Basic Statistic Physician office payment for biosimilars in Medicare Part B 2022
- Premium Statistic Potential biosimilars savings in EU5 countries and the U.S. 2016-2020
- Premium Statistic Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Premium Statistic Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Basic Statistic U.S. specialists and familiarity with biosimilars 2021
- Premium Statistic Major biologics to lose patent protection 2015-2020 by EU5 and U.S. revenue
- Basic Statistic Biosimilars in development and approved by FDA 2019, by manufacturer
- Premium Statistic Number of medication brands that lose patent protection 2004-2020
- Basic Statistic Top branded biologic drugs in the U.S. that will go generic by 2028
Selected statistics
10
- Premium Statistic Savings through generic drug usage in the U.S., by age group share 2024
- Basic Statistic Percentage savings through generic drug usage in the U.S. by payer 2024
- Premium Statistic Savings through generic drug usage in the U.S., by payer 2024
- Basic Statistic Montelukast out-of-pocket cost in the U.S. 2004-2023
- Premium Statistic U.S. top 20 branded drugs based on prescriptions 2014-2015
- Basic Statistic Trazodone out-of-pocket cost in the U.S. 2004-2023
- Basic Statistic Rosuvastatin out-of-pocket cost U.S. 2004-2023
- Basic Statistic Fluticasone out-of-pocket cost in the U.S. 2004-2023
- Premium Statistic Esomeprazole out-of-pocket cost U.S. 2006-2023
- Basic Statistic Esomeprazole prescriptions number U.S. 2007-2023
Other regions
10
- Premium Statistic Size comparison of small-moelcule drugs and biologics 2020
- Basic Statistic Drug cost distribution by drug type in public drug plans Canada 2021/2022
- Premium Statistic Orphan vs. non-orphan drugs median cost per patient per year 2014-2018
- Basic Statistic Expenditure worldwide on diabetes by market 2013-2018
- Premium Statistic Small molecules facing loss of developed market exclusivity 2011-2020
- Premium Statistic Number of PBS approved community pharmacies Australia 2023, by state and territory
- Premium Statistic Medicinal market growth by world region, specialty and traditional 2013-2018
- Premium Statistic Biologic drug costs in select Canadian public drug plans in 2021/2022
- Premium Statistic Value of top worldwide pharmaceutical company acquisitions 1994-2014
- Premium Statistic Retail sales rate of change generic vs. patented drugs in Canada 2007-2018
Related statistics
10
- Premium Statistic Prescription spending per capita for 65+ year-olds in U.S. by insurance 2010-2020
- Basic Statistic Levothyroxine out of pocket price U.S. 2004-2023
- Premium Statistic Potassium chloride out-of-pocket price U.S. 2004-2023
- Basic Statistic Acetaminophen out of pocket price U.S. 2004-2023
- Premium Statistic Acetaminophen/hydrocodone out of pocket price U.S. 2004-2023
- Premium Statistic Loss of Neupogen sales to U.S. biosimilars 2015-2017
- Basic Statistic Losartan out of pocket price U.S. 2004-2023
- Premium Statistic Lisinopril out-of-pocket cost U.S. 2004-2023
- Premium Statistic Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Basic Statistic Metformin out of pocket price U.S. 2004-2023
Further Content: You might find this interesting as well
* For commercial use only
Basic Account
For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
- Free Statistics
Based on your interests
Starter Account
For single users
$199 USD
per month, billed annually
1
- Free Statistics
- Premium Statistics
Professional Account
For teams of up to 99 users
Talk to sales for pricing
- Free + Premium Statistics
- Reports
- Market ÌÇÐÄÆƽâ°æ
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Amgen. (May 30, 2019). Cost-sharing for generic and brand name drugs in the Medicare Part D coverage gap in 2019 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 29, 2026, from /statistics/1088428/cost-sharing-generic-and-brand-drugs-medicare-part-d-coverage-gap-us/
Amgen. "Cost-sharing for generic and brand name drugs in the Medicare Part D coverage gap in 2019." Chart. May 30, 2019. ÌÇÐÄÆƽâ°æ. Accessed July 29, 2026. /statistics/1088428/cost-sharing-generic-and-brand-drugs-medicare-part-d-coverage-gap-us/
Amgen. (2019). Cost-sharing for generic and brand name drugs in the Medicare Part D coverage gap in 2019. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 29, 2026. /statistics/1088428/cost-sharing-generic-and-brand-drugs-medicare-part-d-coverage-gap-us/
Amgen. "Cost-sharing for Generic and Brand Name Drugs in The Medicare Part D Coverage Gap in 2019." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 30 May 2019, /statistics/1088428/cost-sharing-generic-and-brand-drugs-medicare-part-d-coverage-gap-us/
Amgen, Cost-sharing for generic and brand name drugs in the Medicare Part D coverage gap in 2019 ÌÇÐÄÆƽâ°æ, /statistics/1088428/cost-sharing-generic-and-brand-drugs-medicare-part-d-coverage-gap-us/ (last visited July 29, 2026)
Cost-sharing for generic and brand name drugs in the Medicare Part D coverage gap in 2019 [Graph], Amgen, May 30, 2019. [Online]. Available: /statistics/1088428/cost-sharing-generic-and-brand-drugs-medicare-part-d-coverage-gap-us/
Advertisement